Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Spero Therapeutics Second Quarter 202 Earnings Conference Call.
Spero Therapeutics Inc. (SPRO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Anson Investments Amin Nathoo And Moez Kassam | 1,615,469 | $4,684,860 | -58% | 0.67% |
| 2. | Renaissance Technologies Jim Simons | 832,165 | $2,413,279 | -15% | 0% |
| 3. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 510,834 | $1,481,417 | 0.01% | |
| 4. | Stonepine Capital Timothy P. Lynch | 156,888 | $454,975 | 0.45% | |
| 5. | Ionic Capital Management Bart Baum | 150,000 | $435,000 | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.24 | 39,727 | $207,970.85 | 5,321,231 | 2022-04-26 | Filing | |
| $8.79 | 16,885 | $148,392.13 | 5,281,504 | 2022-03-30 | Filing | |
| $8.79 | 33,115 | $291,027.87 | 5,264,619 | 2022-03-30 | Filing | |
| $7.63 | 8,006 | $61,053.76 | 5,231,504 | 2022-03-14 | Filing | |
| $7.63 | 15,702 | $119,743.45 | 5,223,498 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.97 | 6,572 | $12,946.84 | 703,294 | 2025-08-28 | Filing | |
| $1.97 | 1,695 | $3,339.15 | 739,744 | 2025-08-28 | Filing | |
| $0.78 | 24,920 | $19,437.60 | 741,439 | 2025-02-05 | Filing | |
| $0.78 | 27,643 | $21,561.54 | 766,359 | 2025-02-05 | Filing | |
| $0.78 | 3,974 | $3,099.72 | 794,002 | 2025-02-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,993 | $69,547 | 0% | |
| 2. | 32,548 | $61,190 | 0% | |
| 3. | 30,000 | $56,400 | 0.01% |
News See All
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week
We recently published a list of Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week.
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
14 Cheap Penny Stocks to Buy According to Analysts
In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript
Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.96, expectations were $-0.1.
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
In this article, we will take a detailed look at the 15 Cash-Rich Penny Stocks Hedge Funds Are Buying. For a quick overview of such stocks, read our article 5 Cash-Rich Penny Stocks Hedge Funds Are...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript
Ted Jenkins: Thank you, operator, and thank you all for participating in today's conference call.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2023 Financial Results Conference Call.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.